每月一次注射加卡尼单抗预防成人偏头痛：基于证据的描述性综述及在治疗中的潜在地位
Once-monthly galcanezumab for the prevention of migraine in adults: an evidence-based descriptive review and potential place in therapy.
作者信息
Lupi Chiara, Guerzoni Simona, Negro Andrea, Benemei Silvia
机构信息
Headache Centre, Careggi University Hospital, Department of Health Sciences, University of Florence, Florence, Italy,
Medical Toxicology Unit, Headache and Drug Abuse Centre, Department of Biomedical, Metabolic and Neural Sciences, University of Modena e Reggio Emilia, Modena, Italy.
出版信息
Ther Clin Risk Manag. 2019 Apr 11;15:557-569. doi: 10.2147/TCRM.S159690. eCollection 2019.
Abstract
In the last 15 years relevant efforts have been made to demonstrate that calcitonin gene-related peptide (CGRP) antagonism is a valuable and druggable mechanism for treatment or prevention of migraine. Galcanezumab is one of the antibodies developed and studied to prevent migraine by targeting CGRP. The scope of this review is to report data currently available on galcanezumab. According to available data, galcanezumab is safe and efficacious in preventing migraine in episodic migraine patients, also reducing disability and functional impairment due to the disorder. In September 2018, galcanezumab was approved in the USA for the prevention of migraine in adults. The placement of galcanezumab into the current therapeutic scenario will be a revolution for migraine patients, and probably in a less near future also for patients affected by other primary headaches.
摘要
在过去15年里，人们进行了相关努力以证明降钙素基因相关肽（CGRP）拮抗作用是治疗或预防偏头痛的一种有价值且可成药的机制。加卡尼单抗是为通过靶向CGRP预防偏头痛而研发和研究的抗体之一。本综述的范围是报告目前有关加卡尼单抗的可用数据。根据现有数据，加卡尼单抗在预防发作性偏头痛患者的偏头痛方面安全有效，还能减少该疾病导致的残疾和功能损害。2018年9月，加卡尼单抗在美国被批准用于预防成人偏头痛。加卡尼单抗进入当前的治疗方案对偏头痛患者来说将是一场变革，而且可能在不久的将来对其他原发性头痛患者也是如此。
相似文献
1
Once-monthly galcanezumab for the prevention of migraine in adults: an evidence-based descriptive review and potential place in therapy.每月一次注射加卡尼单抗预防成人偏头痛：基于证据的描述性综述及在治疗中的潜在地位
Ther Clin Risk Manag. 2019 Apr 11;15:557-569. doi: 10.2147/TCRM.S159690. eCollection 2019.
2
Reducing Episodic Cluster Headaches: Focus on Galcanezumab.减轻发作性丛集性头痛：聚焦于加卡奈珠单抗。
J Pain Res. 2020 Jul 2;13:1591-1599. doi: 10.2147/JPR.S222604. eCollection 2020.
3
Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial.加巴喷丁在预防阵发性偏头痛中的疗效和安全性：EVOLVE-2 期 3 随机对照临床试验结果。
Cephalalgia. 2018 Jul;38(8):1442-1454. doi: 10.1177/0333102418779543. Epub 2018 May 31.
4
History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment.降钙素基因相关肽（CGRP）拮抗剂治疗的历史和综述：从转化研究到治疗。
Headache. 2018 Nov;58 Suppl 3:238-275. doi: 10.1111/head.13379. Epub 2018 Sep 22.
5
Galcanezumab: a humanized monoclonal antibody for the prevention of migraine and cluster headache.加卡尼单抗：一种用于预防偏头痛和丛集性头痛的人源化单克隆抗体。
Drugs Today (Barc). 2020 Jan;56(1):5-19. doi: 10.1358/dot.2020.56.1.3069863.
6
Anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: Update on a Previous Review After the American Headache Society 60th Scientific Meeting, San Francisco, June 2018.抗降钙素基因相关肽（CGRP）治疗药物：美国头痛学会第 60 届科学会议（2018 年 6 月，旧金山）后对既往综述的更新。
Headache. 2018 Nov;58 Suppl 3:276-290. doi: 10.1111/head.13417.
7
Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention: A Randomized Clinical Trial.加巴喷丁预防偏头痛发作的不同剂量与安慰剂的效果：一项随机临床试验。
JAMA Neurol. 2018 Feb 1;75(2):187-193. doi: 10.1001/jamaneurol.2017.3859.
8
Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2).加巴喷丁在发作性偏头痛中的疗效：3 期研究（EVOLVE-1 和 EVOLVE-2）中根据偏头痛发作频率高低的亚组分析。
J Headache Pain. 2019 Jun 28;20(1):75. doi: 10.1186/s10194-019-1024-x.
9
Galcanezumab: A Review in the Prevention of Migraine and Treatment of Episodic Cluster Headache.加巴喷丁：预防偏头痛和治疗阵发性丛集性头痛的研究进展。
Drugs. 2020 Jun;80(9):893-904. doi: 10.1007/s40265-020-01329-5.
10
100% Response Rate to Galcanezumab in Patients With Episodic Migraine: A Post Hoc Analysis of the Results From Phase 3, Randomized, Double-Blind, Placebo-Controlled EVOLVE-1 and EVOLVE-2 Studies.在发作性偏头痛患者中，Galcanezumab 的应答率达到 100%：来自 3 期、随机、双盲、安慰剂对照 EVOLVE-1 和 EVOLVE-2 研究的事后分析结果。
Headache. 2018 Oct;58(9):1347-1357. doi: 10.1111/head.13427. Epub 2018 Oct 20.
引用本文的文献
1
Effectiveness of galcanezumab on sleep quality, migraine outcome, and multidimensional patient-reported outcome measures: a real-world experience in Turkish patients with episodic and chronic migraine.加卡奈单抗对睡眠质量、偏头痛结局及多维患者报告结局指标的有效性：土耳其发作性和慢性偏头痛患者的真实世界经验
Front Neurol. 2024 Jun 3;15:1411238. doi: 10.3389/fneur.2024.1411238. eCollection 2024.
2
Cortical spreading depression: culprits and mechanisms.皮质扩散性抑制：罪魁祸首和机制。
Exp Brain Res. 2022 Mar;240(3):733-749. doi: 10.1007/s00221-022-06307-9. Epub 2022 Jan 22.
3
Pharmacological Characterization of Orofacial Nociception in Female Rats Following Nitroglycerin Administration.硝酸甘油给药后雌性大鼠口腔面部伤害感受的药理学特征
Front Pharmacol. 2020 Dec 3;11:527495. doi: 10.3389/fphar.2020.527495. eCollection 2020.
4
An Evidence-Based Review of Galcanezumab for the Treatment of Migraine.加卡尼单抗治疗偏头痛的循证综述
Neurol Ther. 2020 Dec;9(2):403-417. doi: 10.1007/s40120-020-00214-3. Epub 2020 Oct 3.
5
Efficacy and safety of galcanezumab for preventive treatment of migraine: a systematic review and meta-analysis.加卡尼单抗预防性治疗偏头痛的疗效与安全性：一项系统评价和荟萃分析
J Neurol. 2021 Jul;268(7):2364-2376. doi: 10.1007/s00415-020-09707-5. Epub 2020 Jan 31.
6
Calcitonin Gene-Related Peptide (CGRP) and Cluster Headache.降钙素基因相关肽（CGRP）与丛集性头痛
Brain Sci. 2020 Jan 6;10(1):30. doi: 10.3390/brainsci10010030.
本文引用的文献
1
Preventive effects of galcanezumab in adult patients with episodic or chronic migraine are persistent: data from the phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and REGAIN studies.加巴喷丁在发作性或慢性偏头痛成年患者中的预防作用是持久的：来自 3 期、随机、双盲、安慰剂对照 EVOLVE-1、EVOLVE-2 和 REGAIN 研究的数据。
J Headache Pain. 2018 Dec 29;19(1):121. doi: 10.1186/s10194-018-0951-2.
2
Patient satisfaction, health care resource utilization, and acute headache medication use with galcanezumab: results from a 12-month open-label study in patients with migraine.加卡尼单抗治疗偏头痛患者的患者满意度、医疗资源利用及急性头痛药物使用情况：一项为期12个月的开放标签研究结果
Patient Prefer Adherence. 2018 Nov 13;12:2413-2424. doi: 10.2147/PPA.S182563. eCollection 2018.
3
Analysis of Initial Nonresponders to Galcanezumab in Patients With Episodic or Chronic Migraine: Results From the EVOLVE-1, EVOLVE-2, and REGAIN Randomized, Double-Blind, Placebo-Controlled Studies.分析加拉曲班治疗发作性或慢性偏头痛初始无应答者：来自 EVOLVE-1、EVOLVE-2 和 REGAIN 随机、双盲、安慰剂对照研究的结果。
Headache. 2019 Feb;59(2):192-204. doi: 10.1111/head.13443. Epub 2018 Nov 21.
4
Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study.加巴喷丁在慢性偏头痛中的应用：一项随机、双盲、安慰剂对照的 REGAIN 研究。
Neurology. 2018 Dec 11;91(24):e2211-e2221. doi: 10.1212/WNL.0000000000006640. Epub 2018 Nov 16.
5
A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine.一项评估加尼卡珠单抗治疗偏头痛患者的 3 期、长期、开放性标签安全性研究。
BMC Neurol. 2018 Nov 9;18(1):188. doi: 10.1186/s12883-018-1193-2.
6
100% Response Rate to Galcanezumab in Patients With Episodic Migraine: A Post Hoc Analysis of the Results From Phase 3, Randomized, Double-Blind, Placebo-Controlled EVOLVE-1 and EVOLVE-2 Studies.在发作性偏头痛患者中，Galcanezumab 的应答率达到 100%：来自 3 期、随机、双盲、安慰剂对照 EVOLVE-1 和 EVOLVE-2 研究的事后分析结果。
Headache. 2018 Oct;58(9):1347-1357. doi: 10.1111/head.13427. Epub 2018 Oct 20.
7
Comparison between prefilled syringe and autoinjector devices on patient-reported experiences and pharmacokinetics in galcanezumab studies.在加卡奈珠单抗研究中，预填充注射器与自动注射器装置在患者报告的体验和药代动力学方面的比较。
Patient Prefer Adherence. 2018 Sep 17;12:1785-1795. doi: 10.2147/PPA.S170636. eCollection 2018.
8
Measures of Functioning in Patients With Episodic Migraine: Findings From a Double-Blind, Randomized, Placebo-Controlled Phase 2b Trial With Galcanezumab.发作性偏头痛患者的功能测量：加奈徳珠单抗的一项双盲、随机、安慰剂对照 2b 期试验结果。
Headache. 2018 Sep;58(8):1225-1235. doi: 10.1111/head.13383. Epub 2018 Aug 14.
9
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Erenumab on Exercise Time During a Treadmill Test in Patients With Stable Angina.一项评价依瑞奈玛单抗对稳定性心绞痛患者跑步机测试中运动时间影响的随机、双盲、安慰剂对照研究。
Headache. 2018 May;58(5):715-723. doi: 10.1111/head.13316.
10
Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial.加巴喷丁在预防阵发性偏头痛中的疗效和安全性：EVOLVE-2 期 3 随机对照临床试验结果。
Cephalalgia. 2018 Jul;38(8):1442-1454. doi: 10.1177/0333102418779543. Epub 2018 May 31.
Zotero 插件